amiselimod vs etrasimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
amiselimod
Developed by Bausch Health under a licence from Tanabe Pharma Corporation
NCT04857112 · Phase 2 · completed
This trial randomly assigned 322 people with ulcerative colitis to one of two amiselimod doses or placebo, with participants and investigators unaware of assignment. The primary measure was change in the modified Mayo Score, which combines the appearance of the bowel lining at endoscopy with clinical disease activity. Scores fell by 2.3 points on amiselimod against 1.6 points on placebo (p=0.002).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Change from Baseline in the modified Mayo Score at Day 85 (Baseline to Day 85): Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002) (met)
Result source: NCT04857112
etrasimod · Velsipity
Marketed by Pfizer and partners
NCT03945188 · Phase 3 · completed
Randomized 2:1, double-blind, placebo-controlled, adequately powered (n=433) phase 3 trial with a hard clinical/endoscopic composite primary endpoint (clinical remission via modified Mayo score incorporating centrally-read endoscopy), and both co-primary endpoint comparisons reached statistical significance in the favorable direction (p<0.001), satisfying the 'strong' definition.
Next expected readout: June 2027 · NCT07782242 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Clinical Remission at Week 12; Percentage of Participants Achieving Clinical Remission at Week 52: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo) (met)
Result source: NCT03945188
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | amiselimod | etrasimod |
|---|---|---|
| Clinical remission (induction) | —Not reported | 27% vs 7.4%+19.6 vs placeboNCT039451886 other results
|
| Clinical remission (maintenance) | —Not reported | 32.1% vs 6.7%+25.4 vs placeboNCT039451883 other results
|
| Clinical response (induction) | —Not reported | 62.4% vs 34.1%+28.3 vs placeboNCT039451886 other results
|
| Endoscopic improvement (induction) | —Not reported | 35% vs 14.1%+20.9 vs placeboNCT039451886 other results
|
| Corticosteroid-free remission (maintenance) | —Not reported | 32.1% vs 6.7%+25.4 vs placeboNCT039451886 other results
|
Clinical remission (induction)
- amiselimod
- —Not reported
- etrasimod
- 27% vs 7.4%+19.6 vs placeboNCT03945188
6 other results
- 24.8% vs 15.2% NCT03996369
- 26.3% vs 0% NCT05061446
- 6.7% vs 0% NCT05061446
- 33% vs 8.1% NCT02447302
- 16% vs 8.1% NCT02447302
- 28.3% vs 11.7% NCT04607837
Clinical remission (maintenance)
- amiselimod
- —Not reported
- etrasimod
- 32.1% vs 6.7%+25.4 vs placeboNCT03945188
3 other results
- 25% vs 7.1% NCT04706793
- 49.1% vs 17.4% NCT03945188
- 26% vs 18.3% NCT04607837
Clinical response (induction)
- amiselimod
- —Not reported
- etrasimod
- 62.4% vs 34.1%+28.3 vs placeboNCT03945188
6 other results
- 62.2% vs 41.1% NCT03996369
- 50.6% vs 32.5% NCT02447302
- 43.7% vs 32.5% NCT02447302
- 55.9% vs 36.7% NCT04607837
- 52.6% vs 7.1% NCT05061446
- 33.3% vs 7.1% NCT05061446
Endoscopic improvement (induction)
- amiselimod
- —Not reported
- etrasimod
- 35% vs 14.1%+20.9 vs placeboNCT03945188
6 other results
- 30.6% vs 18.8% NCT03996369
- 41.8% vs 17.8% NCT02447302
- 22.5% vs 17.8% NCT02447302
- 44.1% vs 20% NCT04607837
- 26.3% vs 0% NCT05061446
- 6.7% vs 0% NCT05061446
Corticosteroid-free remission (maintenance)
- amiselimod
- —Not reported
- etrasimod
- 32.1% vs 6.7%+25.4 vs placeboNCT03945188
6 other results
- 31% vs 7.5% NCT03945188
- 25% vs 7.1% NCT04706793
- 25.2% vs 16.7% NCT04607837
- 25.2% vs 16.7% NCT04607837
- 16.2% vs 16.7% NCT04607837
- 30% vs 30% NCT04607837
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. amiselimod: 1 of 5 rows · etrasimod: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | amiselimod | etrasimod |
|---|---|---|
| Mayo 9 absolute change · score Induction | -2.3 vs -1.6 placebo score @ 12.142857wka,b,c NCT04857112 · Phase 2 · sponsor-reported, not registry data | -2.49 vs -1.5 placebo score @ 12wk2 mgd,a,b,c NCT02447302 · Phase 2 · registry result, not featured evidence show 1 more dose-1.94 vs -1.5 placebo score @ 12wk1 mg NCT02447302 · Phase 2 · registry result, not featured evidence |
| Dropout rate | — | 44.3%2 mge NCT03945188 · Phase 3 · monotherapy show 8 more results10.5%2 mg NCT03996369 · Phase 3 · monotherapy 35.7%2 mg NCT04706793 · Phase 3 · monotherapy 37.4% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 5.9%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 17.9%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 8%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 9.6%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | 3.5%2 mge NCT03945188 · Phase 3 · monotherapy show 8 more results3.8%2 mg NCT03996369 · Phase 3 · monotherapy —2 mg NCT04706793 · Phase 3 · monotherapy 5.2% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 0%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 4.5%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 6%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 7.7%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | 6.9%2 mge NCT03945188 · Phase 3 · monotherapy show 8 more results2.5%2 mg NCT03996369 · Phase 3 · monotherapy 3.6%2 mg NCT04706793 · Phase 3 · monotherapy 6.5% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 0%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 6.3%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 0%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 5.8%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | 2 mge anaemia 8.3% (placebo 9.7%) headache 8.3% (placebo 4.9%) covid-19 6.6% (placebo 5.6%) NCT03945188 · Phase 3 · monotherapy show 8 more results2 mg anaemia 5.9% (placebo 6.9%) headache 4.6% (placebo 1.7%) nausea 4.2% (placebo 1.7%) NCT03996369 · Phase 3 · monotherapy 2 mg headache 14.3% (placebo 14.3%) malaise 10.7% (placebo 0%) pyrexia 10.7% (placebo 14.3%) NCT04706793 · Phase 3 · monotherapy colitis ulcerative 12.3% (placebo 10.1%) covid-19 9.7% (placebo 8.9%) alanine aminotransferase increased 8.4% (placebo 1.3%) NCT04607837 · Phase 2 · registry result, not featured evidence 2 mg alanine aminotransferase increased 5.3% (placebo 0%) back pain 5.3% (placebo 0%) blood creatine phosphokinase increased 5.3% (placebo 0%) NCT05061446 · Phase 2 · registry result, not featured evidence 1 mg stomatitis 11.8% (placebo 0%) anaemia 5.9% (placebo 0%) cataract 5.9% (placebo 0%) NCT05061446 · Phase 2 · registry result, not featured evidence 2 mg colitis ulcerative 14.3% (placebo 16.7%) anaemia 8.9% (placebo 0%) gamma-glutamyltransferase increased 8.9% (placebo 0%) NCT02536404 · Phase 2 · registry result, not featured evidence 2 mg anaemia 6% (placebo 3.7%) headache 6% (placebo 1.9%) colitis ulcerative 4% (placebo 1.9%) NCT02447302 · Phase 2 · registry result, not featured evidence 1 mg upper respiratory tract infection 7.7% (placebo 3.7%) colitis ulcerative 5.8% (placebo 1.9%) anaemia 3.8% (placebo 3.7%) NCT02447302 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 12 weeks versus 12.142857 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
etrasimod
show 10 more results
show 9 more results
show 19 more results
show 5 more results
show 6 more results
show 2 more results
show 8 more results
show 4 more results
show 16 more results
+ 10 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amiselimod's landscape · etrasimod's landscape